← Back
MapLight Therapeutics
MPLT · listed on Nasdaq · worth $376.8 million
$6.78
−10.55% on Nov 2
Ten insider buys in the last year, $66.23 million in all. None in the last two weeks.
Different buyers at onceDirector Troy Cox bought, and Catalyst4's stake rose to 49.9%, within 3 weeks · Aug 18
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
15.8M shares
30% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought MapLight Therapeutics stock and seven insiders sold. 25 of the 67 sales are marked on the filing as planned in advance; most by company executives. The biggest seller was Christopher A. Kroeger, Chief Executive Officer.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
Catalyst4
Bought $50.07M on Aug 14 — 4,400,000 shares at $11.38, held through a trust or family, 17% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Director
Timothy John Garnett
Bought $252.7K on Feb 10 — 14,124 shares at $17.89, held through a trust or family, 100% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Director
George Pavlov
Bought $186.3K on Feb 18 — 10,658 shares at $17.48, 100% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Planned sales
Form 144 notices filed for MapLight Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Kristopher Hanson filed to sell 9,020 shares on 15 Oct; sold 9,020 by 15 OctNotice on SEC.gov
Executive Erin Pennock Foff filed to sell 15,355 shares on 15 Oct; sold 15,355 by 15 OctNotice on SEC.gov
CFO Jonathan Gillis filed to sell 10,167 shares on 15 Oct; sold 10,167 by 15 OctNotice on SEC.gov
Big investors
People and funds that reported owning 5% or more of MapLight Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.Pivotal bioVenture Partners Fund II1.2%Aug 20
Filed by someone who owns 5% or more and may try to influence how the company is run. · updateCatalyst449.9%Aug 18Reported stake, oldest first: 47.9% (Aug 3) → 49.9% (Aug 18)Also bought on the open market
Filed by someone who owns 5% or more and may try to influence how the company is run. · updateCatalyst447.9%Aug 3
Filed by someone who owns 5% or more and may try to influence how the company is run. · updateNovo Holdings4.9%Jul 31
Each history starts at the oldest report we hold.
All reports
Every insider trade and SEC report we hold for MapLight Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
74 more with Pro →Analysts, earnings and news
Analysts' price target
$26.69 average
13 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
0 of 4 quarters above
Q2 '26−$1.32 a share−$0.01
Q1 '26−$1.34 a share−$0.25
Q4 '25−$2.47 a share−$1.64
Q3 '25−$37.18 a share−$35.45